Labcorp Holdings Inc.
LH Healthcare Diagnostics & Research
Labcorp Holdings Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.0 billion, up 7.25% from fiscal 2024.
- Revenue
- +6.92%
- EPS
- +3.18%
- Free cash flow
- +44.7%
- Total debt
- +3.21%
Quarter to September 2026, against a year earlier
Follow LH
Alert me
Labcorp Holdings Inc. (LH) P/S ratio
As of 5 November 2026, Labcorp Holdings Inc. (LH) trades at a P/S ratio of 2.0×. Over the past ten years it has ranged from 0.8× (March 2020) to 2.0× (October 2026); the current reading is higher than 100% of that period. That is below the Diagnostics & Research industry median of 4.2× and below the Healthcare sector median of 3.5×.
P/S ratio, daily
Embed this chart
Annual newest first
| Period | P/S ratio | Change |
|---|---|---|
| FY2025 | 1.5× | 1.16% |
| FY2024 | 1.5× | (11.20%) |
| FY2023 | 1.7× | 6.79% |
| FY2022 | 1.6× | (21.06%) |
| FY2021 | 2.0× | 63.26% |
| FY2020 | 1.2× | (1.15%) |
| FY2019 | 1.2× | 26.79% |
| FY2018 | 1.0× | (29.88%) |
| FY2017 | 1.4× | 16.42% |
| FY2016 | 1.2× | (2.15%) |
Quarterly newest first
| Period | P/S ratio | Change |
|---|---|---|
| Sep 2026 | 1.7× | 7.38% |
| Jun 2026 | 1.6× | 2.70% |
| Mar 2026 | 1.6× | 3.77% |
| Dec 2025 | 1.5× | (13.67%) |
| 43 more quarters | Free account |
Against its own ten years
P/S ratio against peers
| Company | P/S ratio |
|---|---|
| LH Labcorp Holdings Inc. | 2.0× |
| DGX Quest Diagnostics Incorporated compare | 2.4× |
| IQV IQVIA Holdings Inc. compare | 2.5× |
| MEDP Medpace Holdings, Inc. compare | 6.2× |
| A Agilent Technologies, Inc. compare | 6.6× |
| ILMN Illumina, Inc. compare | 7.0× |
| WAT Waters Corporation compare | 8.0× |
| MTD Mettler-Toledo International, Inc. compare | 8.2× |
| GH Guardant Health, Inc. compare | 16.2× |
| Diagnostics & Research industry median | 4.2× |
| Healthcare sector median | 3.5× |
| Market median | 1.9× |
What P/S ratio is
Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.
(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)
More on LH
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement